| DC23140 |
AF38469
Featured
|
AF38469 is a potent, selective, orally bioavailable Sortilin inhibitor with IC50 of 330 nM, shows no activity against the NTR1 receptor as well as a panel of targets known to bind acidic molecules (δ-Opioid, GPR40, PPARδ, EP1, Angiotensin AT1, Endothelin |
|
| DC11170 |
AF64394
Featured
|
AF64394 is a potent, selective GPR3 inverse agonist with pIC50 of 7.3, displays >100-fold selectivity over GPR6 and GPR12. |
|
| DC3164 |
BIBW2992-MA2 (Afatinib dimaleate)
Featured
|
Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2. |
|
| DC10513 |
AFN-1252(Debio 1452)
Featured
|
AFN-1252(Debio 1452) is a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis at concentrations of ≤0.12 μg/ml. |
|
| DC9764 |
Afoxolaner
Featured
|
Afoxolaner is an isoxazoline that inhibits insect and acarine ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), blocking pre and post synaptic transfer of chloride ions across cell membranes. |
|
| DC10844 |
Aftin-4
Featured
|
Aftin-4, an amyloid forty-two inducer, activates γ-secretase, promoting the generation of amyloid-β-1-42 (Aβ1-42) from amyloid-β protein precursor. |
|
| DC7994 |
Afuresertib HCl
Featured
|
Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). |
|
| DC8411 |
Afuresertib
Featured
|
Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2. |
|
| DC10589 |
AG 1406
Featured
|
AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 . |
|
| DC8051 |
AG-120 (Ivosidenib)
Featured
|
AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein. |
|
| DC5106 |
AG14361
Featured
|
AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM. It is at least 1000-fold more potent than the benzamides. |
|
| DC1078 |
AG-1478 (Tyrphostin AG-1478)
Featured
|
AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM. |
|
| DC8079 |
AG-1557
Featured
|
AG-1557 is an ultra-potent inhibitor of epidermal growth factor receptor tyrosine kinase (EGFRK). |
|
| DC1080 |
Tyrphostin 9（AG-17）
Featured
|
AG-17 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431. |
|
| DC7051 |
AG-18
Featured
|
AG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 40 μM. |
|
| DC8374 |
AG-221(Enasidenib)
Featured
|
AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein. |
|
| DC12499 |
AG-270
Featured
|
AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM. |
|
| DC2096 |
AG490
Featured
|
AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively. |
|
| DC10623 |
AG-494
Featured
|
AG-494 is an inhibitor of epidermal growth factor receptor kinase with an IC50 value of 1 µM in HT-22 cells. |
|
| DC10439 |
Vorasidenib (AG881)
Featured
|
AG-881 is a potent and selective orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1) in the cytoplasm and type 2 (IDH2). |
|
| DC12382 |
AG-99
Featured
|
AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431. |
|
| DC5050 |
AGI-5198
Featured
|
AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM. |
|
| DC7174 |
AGI-6780
Featured
|
AGI-6780 is the first highly potent and selective small molecule inhibitor of isocitrate dehydrogenases, which binds in an allosteric manner at the dimer interface of mutant IDH2-R140Q (IC50=23 nM). |
|
| DC8437 |
AGK2
Featured
|
AGK2 is a potent, and selective SIRT2 inhibitor with IC50 of 3.5 μM. |
|
| DC7632 |
AHAS inhibitor(BTB06584)
Featured
|
AHAS inhibitor is a novel acetohydroxyacid synthase(AHAS) inhibitor, a promising drug target against Mycobacterium tuberculosis (MTB). |
|
| DC8735 |
AHU-377 hemicalcium salt
Featured
|
AHU-377 is an inhibitor of neprilysin with IC50 value of 5 nM. |
|
| DC20305 |
AI-10-104
Featured
|
AI-10-104 is a small molecule inhibitor that interferes with CBFβ binding to RUNX proteins with IC50 of 1.25 uM in FRET assays. |
|
| DC9402 |
Letermovir(AIC-246)
Featured
|
AIC246 is a novel anti-CMV compound which targets the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors. |
|
| DC23900 |
AICAR phosphate
Featured
|
AICAR phosphate (Acadesine, AICA Riboside, NSC 105823) is a selective AMPK activator in both hepatocytes and adipocytes. |
|
| DC9330 |
AIM-100
Featured
|
AIM-100 is a small molecule inhibitor of Ack1 with an IC50 of 24 nM
IC50 value: 24 nM [3]
Target: Ack1
Ack1 inhibitor AIM-100 not only inhibited Ack1 activation but also suppressed AKT tyrosine phosphorylation, leading to cell cycle arrest in the G1 ph |
|
